Bacteriophage procurement for therapeutic purposes

Frontiers in Microbiology

Volumn 7, Issue AUG, 2016, Pages

  Weber Dabrowska, Beata ^a   Jończyk Matysiak, Ewa ^a   Zaczek, Maciej ^a   Łobocka, Małgorzata ^b,c   Łusiak Szelachowska, Marzanna ^a   Górski, Andrzej ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antibiotic resistance; Bacteriophage isolation; Experimental phage therapy; Therapeutic phages; Treatment of bacterial infections

Indexed keywords

ANTIBIOTIC AGENT;

ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIOLYSIS; BACTERIOPHAGE; BACTERIOPHAGE TYPING; BIOFILM; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; MYOVIRIDAE; NONHUMAN; PODOVIRIDAE; PROPIONIBACTERIUM ACNES; REVIEW; SALMONELLA ENTERICA SEROVAR CHOLERAESUIS; SIPHOVIRIDAE; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGE;

EID: 84988851301     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.01177     Document Type: Review

References (153)

1. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., and Kutter, E. M. (2011a). Phage treatment of human infections. Bacteriophage 1, 66-85. doi: 10.4161/bact.1.2.15845
2. Abedon, S. T., and Thomas-Abedon, C. (2010). Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11, 28-47. doi: 10.2174/138920110790725410
3. Abedon, S. T., Thomas-Abedon, C., Thomas, A., and Mazure, T. (2011b). Bacteriophage prehistory: is or is not Hankin, 1896, a phage reference? Bacteriophage 1, 174-178. doi: 10.4161/bact.1.3.16591
4. Abedon, S. T., and Yin, J. (2009). Bacteriophage plaques: theory and analysis. Methods Mol. Biol. 501, 161-174. doi: 10.1007/978-1-60327-164-6_17
5. Ackermann, H. W. (2005). "Bacteriophage classification, " in Bacteriophages: Biology and Applications, eds E. Kutter and A. Sulakvelidze (Boca Raton, FL: CRC Press), 169-187.
6. Ackermann, H. W., and Heldal, M. (2010). Basic electron microscopy of aquatic viruses. Man. Aquat. Viral Ecol. 18, 182-192. doi: 10.4319/mave.2010.978-0-9845591-0-7.182
7. Ackermann, H. W., Tremblay, D., and Moinaeu, S. (2004). Long term bacteriophage preservation. World Fed. Cult. Collection Newslett. 38, 35-40.
8. Adams, M. H. (1959). "Enumeration of bacteriophage particles, " in The Bacteriophages, ed. M. H. Adams (New York, NY: Interscience Publishers Inc.).
9. Adriaenssens, E. M., Lehman, S. M., Vandersteegen, K., Vandenheuvel, D., Philippe, D. L., Cornelissen, A., et al. (2012). CIM monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles. Virology 434, 265-270. doi: 10.1016/j.virol.2012.09.018
10. Alfahdel, M., Puapermpoonsiri, U., Ford, S. J., McInnes, F. J., and van der Walle, C. F. (2011). Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: in vitro evaluation. Int. J. Pharm. 416, 280-287. doi: 10.1016/j.ijpharm.2011.07.006
11. Arias, C. A., and Murray, B. E. (2009). Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N. Engl. J. Med. 360, 439-443. doi: 10.1056/NEJMp0804651
12. Beheshti Maal, K., Soleimani Delfan, A., and Salmanizadeh, S. (2015). Isolation and identification of two novel Escherichia coli bacteriophages and their application in wastewater treatment and coliform's phage therapy. Jundishapur J. Microbiol. 8:e14945. doi: 10.5812/jjm.14945
13. Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., et al. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32, 1146-1150. doi: 10.1038/nbt.3043
14. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A. N., Powell, B., et al. (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204-210. doi: 10.1128/IAI.70.1.204-210.2002
15. Borysowski, J., and Górski, A. (2008). Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 12, 466-471. doi: 10.1016/j.ijid.2008.01.006
16. Borysowski, J., Miedzybrodzki, R., and Górski, A. (2014). Phage Therapy: Current Research and Applications. Norfolk: Caister Academic Press.
17. Brown, T. L., Petrovski, S., Dyson, Z. A., Seviour, R., and Tucci, J. (2016). The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes Growth. PLoS ONE 11:e0151184. doi: 10.1371/journal.pone.0151184
18. Bull, J. J., and Gill, J. J. (2014). The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front. Microbiol. 5:618. doi: 10.3389/fmicb.2014.00618
19. Bull, J. J., Vimr, E. R., and Molineux, I. J. (2010). A tale of tails: sialidase is key to success in a model of phage therapy against k1-capsulated Escherichia coli. Virology 398, 79-86. doi: 10.1016/j.virol.2009.11.040
20. Burrowes, B., Harper, D. R., Anderson, J., McConville, M., and Enright, M. (2011). Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev. Anti Infect. Ther. 9, 775-785. doi: 10.1586/eri.11.90
21. Chan, B. K., and Abedon, S. T. (2012). Phage therapy pharmacology: phage cocktails. Adv. Appl. Microbiol. 78, 1-23. doi: 10.1016/B978-0-12-394805-2.00001-4
22. Chhibber, S., Kaur, T., and Kaur, S. (2013). Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS ONE 8:e56022. doi: 10.1371/journal.pone.0056022
23. Chhibber, S., and Kumari, S. (2012). "Application of therapeutic phages in medicine, " in Bacteriophages, ed. I. Kurtboke (Rijeka: InTechOpen).
24. Clark, J. R., and March, J. B. (2006). Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol. 24, 212-218. doi: 10.1016/j.tibtech.2006.03.003
25. Clarke, T. (2003). Drug companies snub antibiotics as pipeline threatens to run dry. Nature 425, 225. doi: 10.1038/425225a
26. Colom, J., Cano-Sarabia, M., Otero, J., Cortés, P., Maspoch, D., and Llagostera, M. (2015). Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl. Environ. Microbiol. 81, 4841-4849. doi: 10.1128/AEM.00812-15
27. Cooper, C. J., Denyer, S. P., and Maillard, J. Y. (2014). Stability and purity of a bacteriophage cocktail preparation for nebuliser delivery. Lett. Appl. Microbiol. 58, 118-122. doi: 10.1111/lam.12161
28. Cornelissen, A., Ceyssen, P., T'Syen, J., Van Praet, H., Noben, J., Shaburova, O. V., et al. (2011). The T7-related Pseudomonas putida phage f15 displays virion-associated biofilm degradation properties. PLoS ONE 6:e18597. doi: 10.1371/journal.pone.0018597
29. Dabrowska, K., Kazmierczak, Z., Majewska, J., Miernikiewicz, P., Piotrowicz, A., Wietrzyk, J., et al. (2014). Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment. Future Microbiol. 9, 861-869. doi: 10.2217/fmb.14.50
30. David, H. L., Clavel, S., and Clement, F. (1980). Adsorption and growth of the bacteriophage D29 in selected mycobacteria. Ann. Virol. 131E, 167-184.
31. Davies, E. V., Winstanley, C., Fothergill, J. L., and James, C. E. (2016). The role of temperate bacteriophages in bacterial infection. FEMS Microbiol. Lett. 363:fnw015. doi: 10.1093/femsle/fnw015
32. Denou, E., Bruttin, A., Barretto, C., Ngom-Bru, C., Brüssow, H., and Zuber, S. (2009). T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388, 21-30. doi: 10.1016/j.virol.2009.03.009
33. Deris, J. B., Kim, M., Zhang, Z., Okano, H., Hermsen, R., Groisman, A., et al. (2013). The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria. Science 342, 1237435. doi: 10.1126/science.1237435
34. D'Hérelle, F. (1917). Sur un microbe invisible antagoniste des bacilles dysentériques. C. R. Acad. Sci. Ser. D 165, 373-375.
35. D'Herelle, F. (1938). Le Phénomène de la Guérison des Maladies Infectieuses (The Phenomenon of the Cure in Infectious Diseases). Paris: Masson.
36. Dini, C., Islan, G. A., de Urraza, P. J., and Castro, G. R. (2012). Novel biopolymer matrices for microencapsulation of phages: enhanced protection against acidity and protease activity. Macromol. Biosci. 12, 1200-1208. doi: 10.1002/mabi.201200109
37. Dubos, R. J., Straus, J. H., and Pierce, C. (1943). The multiplication of bacteriophage in vivo and its protective effects against an experimental infection with Shigella dysenteriae. J. Exp. Med. 78, 161-168. doi: 10.1084/jem.78.3.161
38. Esteban, P. P., Alves, D. R., Enright, M. C., Bean, J. E., Gaudion, A., Jenkins, A. T., et al. (2014). Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions. Biotechnol. Prog. 30, 932-944. doi: 10.1002/btpr.1898
39. Fischer, S., Kittler, S., Klein, G., and Glünder, G. (2013). Microplate-test for the rapid determination of bacteriophage-susceptibility of Campylobacter isolates-development and validation. PLoS ONE 8:e53899. doi: 10.1371/journal.pone.0053899
40. Fortier, L. C., and Moineau, S. (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Methods Mol. Biol. 501, 203-219. doi: 10.1007/978-1-60327-164-6_19
41. Fortuna, W., Miedzybrodzki, R., Weber-Dabrowska, B., and Górski, A. (2008). Bacteriophage therapy in children: facts and prospects. Med. Sci. Monit. 14, 126-132.
42. Gill, J., and Hyman, P. (2010). Phage choice, isolation, and preparation for the phage therapy. Curr. Pharm. Biotechnol. 11, 2-14. doi: 10.2174/138920110790725311
43. Gill, J., and Young, R. F. II. (2011). "Therapeutic applications of phage biology: history, practice and recommendations, " in Emerging Trends in Antibacterial Discovery: Answering the Call to Arms, eds A. A. Miller and P. F. Miller (Norfolk: Caister Adademic Press).
44. Golec, P., Dabrowski, K., Hejnowicz, M. S., Gozdek, A., Los, J. M., Wêgrzyn, G., et al. (2011). A reliable method for storage of tailed phages. J. Microbiol. Methods 84, 486-489. doi: 10.1016/j.mimet.2011.01.007
45. Goodridge, L., and Abedon, S. T. (2008). Bacteriophage biocontrol-the technology matures. Microbiol. Aust. 29, 48-49.
46. Goodridge, L. D. (2010). Designing phage therapeutics. Curr. Pharm. Biotechnol. 11, 15-27. doi: 10.2174/138920110790725348
47. Górski, A., Borysowski, J., Miedzybrodzki, R., and Weber-Dabrowska, B. (2007). "Bacteriophages in medicine, " in Bacteriophage: Genetics and Microbiology, eds Grath S Mc and D. van Sinderen (Norfolk: Caister Academic Press), 125-158.
48. Górski, A., Dabrowska, K., Hodyra-Stefaniak, K., Borysowski, J., Miedzybrodzki, R., and Weber-Dabrowska, B. (2015). Phages targeting infected tissues: novel approach to phage therapy. Future Microbiol. 10, 199-204. doi: 10.2217/fmb.14.126
49. Górski, A., Miedzybrodzki, R., Borysowski, J., Dabrowska, K., Wierzbicki, P., Ohams, M., et al. (2012). Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41-71. doi: 10.1016/B978-0-12-394438-2.00002-5
50. Górski, A., Miedzybrodzki, R., Borysowski, J., Weber-Dabrowska, B., Lobocka, M., Fortuna, W., et al. (2009). Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs 10, 766-774.
51. Gratia, A. (1936). Des relations numeriques entre bacteries lysogenes et particles de bacteriophage. Ann. Inst. Pasteur 57, 652-676.
52. Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., et al. (2012). A method for generation phage cocktail with great therapeutic potential. PLoS ONE 7:e31698. doi: 10.1371/journal.pone.0031698
53. Gupta, R., and Prasad, V. (2011). Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr. Microbiol. 62, 255-260. doi: 10.1007/s00284-010-9699-x
54. Gutiérrez, D., Vandenheuvel, D., Martínez, B., Rodríguez, A., Lavigne, R., and García, P. (2015). Two phages, phiIPLA-RODI and phiIPLA-C1C, lyse mono-and dual-species staphylococcal biofilms. Appl. Environ. Microbiol. 81, 3336-3348. doi: 10.1128/AEM.03560-14
55. Hankin, M. E. (1896). L'action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann. Inst. Pasteur 10, 511-523.
56. Hanlon, G. W. (2007). Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents 30, 118-128. doi: 10.1016/j.ijantimicag.2007.04.006
57. Hargreaves, K. R., Flores, C. O., Lawley, T. D., and Clokie, M. R. (2014). Abundant and diverse clustered regularly interspaced short palindromic repeat spacers in Clostridium difficile strains and prophages target multiple phage types within this pathogen. MBio 5:e1045-13. doi: 10.1128/mBio.01045-13
58. Hendrix, R. W. (2002). Bacteriophages: evolution of the majority. Theor. Popul. Biol. 61, 471-480. doi: 10.1006/tpbi.2002.1590
59. Hendrix, R. W. (2008). "Phage evolution, " in Bacteriophage Ecology, ed. S. T. Abedon (Cambridge: Cambridge University Press), 177-194.
60. Hendrix, R. W., Smith, M. C. M., Burns, R. N., Ford, M. E., and Hatfull, G. F. (1999). Evolutionary relationships among diverse bacteriophages and prophages: all the world's a phage. Proc. Natl. Acad. Sci. U.S.A. 96, 2192-2197. doi: 10.1073/pnas.96.5.2192
61. Henein, A. (2013). What are the limitations on the wider therapeutic use of phage? Bacteriophage 3:e24872. doi: 10.4161/bact.24872
62. Hobley, L., King, J. R., and Sockett, R. E. (2006). Bdellovibrio predation in the presence of decoys: three-way bacterial interactions revealed by mathematical and experimental analyses. Appl. Environ. Microbiol. 72, 6757-6765. doi: 10.1128/AEM.00844-06
63. Hyman, P., and Abedon, S. T. (2009). Practical methods for determining phage growth parameters. Methods Mol. Biol. 501, 175-202. doi: 10.1007/978-1-60327-164-6_18
64. Hyman, P., and Abedon, S. T. (2010). Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 70, 217-248. doi: 10.1016/S0065-2164(10)70007-1
65. Jensen, E. C., Schrader, H. S., Rieland, B., Thompson, T. L., Lee, K. W., Nickerson, K. W., et al. (1998). Prevalence of broad-host-range lytic bacteriophages of Sphaerotilus natans, Escherichia coli, and Pseudomonas aeruginosa. Appl. Environ. Microbiol. 64, 575-580.
66. Jonczyk, E., Klak, M., Miedzybrodzki, R., and Górski, A. (2011). The influence of external factors on bacteriophages-review. Folia Microbiol. 56, 191-200. doi: 10.1007/s12223-011-0039-8
67. Jonczyk-Matysiak, E., Lusiak-Szelachowska, M., Klak, M., Bubak, B., Miedzybrodzki, R., Weber-Dabrowska, B., et al. (2015). The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J. Immunol. Res. 2015:482863. doi: 10.1155/2015/482863
68. Kaur, S., Harjai, K., and Chhibber, S. (2012). Methicillin-resistant Staphylococcus aureus phage plaque size enhancement using sublethal concentrations of antibiotics. Appl. Environ. Microbiol. 78, 8227-8233. doi: 10.1128/AEM.02371-12
69. Keen, E. C. (2012). Phage therapy: concept to cure. Front. Microbiol. 3:238. doi: 10.3389/fmicb.2012.00238
70. Keller, R., and Traub, N. (1974). The characterization of Bacteroides fragilis bacteriophage recovered from animal sera: observations on the nature of bactericides phage carrier cultures. J. Gen. Virol. 24, 179-189. doi: 10.1099/0022-1317-24-1-179
71. Khalifa, L., Brosh, Y., Gelman, D., Coppenhagen-Glazer, S., Beyth, S., Poradosu-Cohen, R., et al. (2015). Targeting Enterococcus faecalis biofilms with phage therapy. Appl. Environ. Microbiol. 81, 2696-2705. doi: 10.1128/AEM.00096-15
72. Khawaja, K. A., Rauf, M., Abbas, Z., and Rehman, S. (2016). A virulent phage JHP against Pseudomonas aeruginosa showed infectivity against multiple genera. J. Basic Microbiol. doi: 10.1002/jobm.201500764 [Epub ahead of print].
73. Kim, K. P., Cha, J. D., Jang, E. H., Klumpp, J., Hagens, S., Hardt, W. D., et al. (2008). PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol. 1, 247-257. doi: 10.1111/j.1751-7915.2008.00028.x
74. Kleiner, M., Hooper, L. V., and Duerkop, B. A. (2015). Evaluation of methods to purify virus-like particles for metagenomic sequencing of intestinal viromes. BMC Genomics 16:7. doi: 10.1186/s12864-014-1207-4
75. Krylov, V., Shaburova, O., Krylov, S., and Pleteneva, E. (2012). A genetic approach to the development of new therapeutic phages to fight Pseudomonas aeruginosa in wound infections. Viruses 5, 15-53. doi: 10.3390/v5010015
76. Krylov, V. N. (2014). Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy. Adv. Virus Res. 88, 227-278. doi: 10.1016/B978-0-12-800098-4.00005-2
77. Kutter, E. (2009). Phage host range and efficiency of plating. Methods Mol. Biol. 501, 141-149. doi: 10.1007/978-1-60327-164-6_14
78. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., et al. (2010). Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69-86. doi: 10.2174/138920110790725401
79. Kutter, E., Kuhl, S., Alavidze, Z., and Blasdel, B. G. (2012). "Chapter: 112, Phage therapy: bacteriophages as natural, self-limiting antibiotics, " in Textbook of Natural Medicine, 4th Edn. eds J. E. Pizzorno and M. T. Murray (London: Elsevier Churchill Livingstone), 945-956.
80. Kwiatek, M., Parasion, S., Mizak, L., Gryko, R., Bartoszcze, M., and Kocik, J. (2012). Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus strains. Arch. Virol. 157, 225-234. doi: 10.1007/s00705-011-1160-3
81. Latz, S., Wahida, A., Arif, A., Häfner, H., Hoß, M., Ritter, K., et al. (2016). Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria. J. Basic Microbiol. doi: 10.1002/jobm.201600108 [Epub ahead of print].
82. Lin, L., Honh, W., Ji, X., Han, J., Huang, L., and Wei, Y. (2010). Isolation and characterization of an extremely long tail Thermus bacteriophage from Tegchong hot springs in China. J. Basic Microbiol. 50, 452-456. doi: 10.1002/jobm.201000116
83. Lobocka, M., Hejnowicz, M. S., Gagala, U., Weber-Dabrowska, B., Wêgrzyn, G., and Dadlez, M. (2014). "The first step to bacteriophage therapy-how to choose the correct phage, " in Phage Therapy: Current Research and Applications, eds J. Borysowski, R. Miedzybrodzki, and A. Górski (Norfolk: Caister Academic Press).
84. Loc-Carrillo, C., and Abedon, S. T. (2011). Pros and cons of phage therapy. Bacteriophage 1, 111-1114. doi: 10.4161/bact.1.2.14590
85. Los, J. M., Golec, P., Wêgrzyn, G., Wêgrzyn, A., and Los, M. (2008). Development of simple method for plating of Escherichia coli bacteriophages forming very small or no plaques under standard conditions. Appl. Environ. Microbiol. 74, 5113-5120. doi: 10.1128/AEM.00306-08
86. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Miedzybrodzki, R., Klak, M., Fortuna, W., et al. (2014). Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 1-10. doi: 10.1089/vim.2013.0128
87. Ly-Chatain, M. H. (2014). The factors affecting effectiveness of treatment in phages therapy. Front. Microbiol. 5:51. doi: 10.3389/fmicb.2014.00051
88. Ma, Y., Li, E., Qi, Z., Li, H., Wei, X., Lin, W., et al. (2016). Isolation and molecular characterisation of Achromobacter phage phiAxp-3, an N4-like bacteriophage. Sci. Rep. 6:24776. doi: 10.1038/srep24776
89. Ma, Y., Pacan, J. C., Wang, Q., Xu, Y., Huang, X., Korenevsky, A., et al. (2008). Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery. Appl. Environ. Microbiol. 74, 4799-4805. doi: 10.1128/AEM.00246-08
90. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., et al. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268-281. doi: 10.1111/j.1469-0691.2011.03570.x
91. Matsuzaki, S., Uchiyama, J., Takemura-Uchiyama, I., and Daibata, M. (2014). Perspective: the age of the phage. Nature 509:S9. doi: 10.1038/509S9a
92. Mattila, S., Ruotsalainen, P., and Jalasvuori, M. (2015). On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front. Microbiol. 6:1271. doi: 10.3389/fmicb.2015.01271
93. McCallin, S., Alam Sarker, S., Barretto, C., Sultana, S., Berger, B., Huq, S., et al. (2013). Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 1, 187-196. doi: 10.1016/j.virol.2013.05.022
94. McLaughlin, M. R. (2007). Simple colorimetric microplate test of phage lysis in Salmonella enterica. J. Microbiol. Methods 69, 394-398. doi: 10.1016/j.mimet.2007.01.006
95. McLaughlin, M. R., and Balaa, M. F. (2006). Enhanced contrast of bacteriophage plaques in Salmonella with ferric ammonium citrate and sodium thiosulfate (FACST) and tetrazolium red (TZR). J. Microbiol. Methods 65, 318-323. doi: 10.1016/j.mimet.2005.08.008
96. Merabishvili, M., Pirnay, J. P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4:e4944. doi: 10.1371/journal.pone.0004944
97. Merabishvili, M., Vervaet, C., Pirnay, J.-P., De Vos, D., Verbeken, G., Mast, J., et al. (2013). Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS ONE 8:e68797. doi: 10.1371/journal.pone.0068797
98. Miedzybrodzki, R., Borysowski, J., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., et al. (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121. doi: 10.1016/B978-0-12-394438-2.00003-7
99. Mirzaei, K. M., and Nilsson, A. S. (2015). Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS ONE 10:e0118557. doi: 10.1371/journal.pone.0118557
100. Moellering, R. C. (2010). NDM-1-a cause for worldwide concern. N. Engl. J. Med. 363, 2377-2379. doi: 10.1056/NEJMp1011715
101. Moradpour, Z., and Ghasemian, A. (2011). Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol. Adv. 29, 732-738. doi: 10.1016/j.biotechadv.2011.06.003
102. Naghavi, N. S., Golgoljam, M., and Akbari, M. (2013). Effect of three sewage isolated bacteriophages on the multidrug resistant pathogenic bacteria. J. Biol. Sci. 13, 422-426. doi: 10.3923/jbs.2013.422.426
103. Narasimhaiah, M. H., Asrani, J. Y., Palaniswamy, S. M., Bhat, J., George, S. E., Srinivasan, R., et al. (2013). Therapeutic potential of Staphylococcal bacteriophages for nasal decolonization of Staphylococcus aureus in mice. Adv. Microbiol. 3, 52-60. doi: 10.4236/aim.2013.31008
104. NIH (2014). NIAID's Antibacterial Resistance Program: Current Status and Future Directions. Available at: http://www.niaid.nih.gov/topics/antimicrobialresistance/documents/arstrategicplan2014.pdf (accessed September 23, 2015).
105. Nilsson, A. S. (2014). Phage therapy-constraints and possibilities. Ups. J. Med. Sci. 119, 192-198. doi: 10.3109/03009734.2014.902878
106. O'Flaherty, S., Ross, R. P., Meaney, W., Fitzgerald, G. F., Elbreki, M. F., and Coffey, A. (2005). Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. 71, 1836-1842. doi: 10.1128/AEM.71.4.1836-1842.2005
107. O'Flynn, G., Ross, R. P., Fitzgerald, G. F., and Coffey, A. (2004). Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl. Environ. Microbiol. 70, 3417-3424. doi: 10.1128/AEM.70.6.3417-3424.2004
108. Oslizlo, A., Miernikiewicz, P., Piotrowicz, A., Owczarek, B., Kopciuch, A., Figura, G., et al. (2011). Purification of phage display-modified bacteriophage T4 by affinity chromatography. BMC Biotechnol. 11:59. doi: 10.1186/1472-6750-11-59
109. Parra, B., and Robeson, J. (2016). Selection of polyvalent bacteriophages infecting Salmonella enterica serovar Choleraesuis. Electron. J. Biotechnol. 21, 72-76. doi: 10.1016/j.ejbt.2016.01.00
110. Periasamy, D., and Sundaram, A. (2013). A novel approach for pathogen reduction in wastewater treatment. J. Environ. Health Sci. Eng. 11, 12. doi: 10.1186/2052-336X-11-12
111. Pires, D. P., Oliveira, H., Melo, L. D., Sillankorva, S., and Azeredo, J. (2016). Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl. Microbiol. Biotechnol. 100, 2141-2151. doi: 10.1007/s00253-015-7247-0
112. Pirnay, J. P., Blasdel, B. G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J. R., et al. (2015). Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173-2179. doi: 10.1007/s11095-014-1617-7
113. Pirnay, J. P., Verbeken, G., Rose, T., Jennes, S., Zizi, M., Huys, I., et al. (2012). Introducing yesterday's phage therapy in today's medicine. Future Virol. 7, 379-390. doi: 10.2217/fvl.12.24
114. Puapermpoonsiri, U., Ford, S. J., and Walle, C. F. (2010). Stabilization of bacteriophage during freeze drying. Int. J. Pharm. 389, 168-175. doi: 10.1016/j.ijpharm.2010.01.034
115. Puapermpoonsiri, U., Spencer, J., and van der Walle, C. F. (2009). A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur. J. Pharm. Biopharm. 72, 26-33. doi: 10.1016/j.ejpb.2008.12.001
116. Reyes, A., Semenkovich, N. P., Whiteson, K., Rohwer, F., and Gordon, J. I. (2012). Going viral: next-generation sequencing applied to phage populations in the human gut. Nat. Rev. Microbiol. 10, 607-617. doi: 10.1038/nrmicro2853
117. Rose, T., Verbeken, G., Vos, D. D., Merabishvili, M., and Vaneechoutte, M. (2014). Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burns Trauma 4, 66-73.
118. Sahin, F., Karasartova, D., Ozsan, T. M., Gerçeker, D., and Kiyan, M. (2013). Identification of a novel lytic bacteriophage obtained from clinical MRSA isolates and evaluation of its antibacterial activity. Mikrobiyol. Bul. 47, 27-34. doi: 10.5578/mb.3790
119. Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., et al. (2016). Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trialin children from Bangladesh. EBioMedicine 4, 124-137. doi: 10.1016/j.ebiom.2015.12.023
120. Schade, A., and Caroline, L. (1944a). The preparation of a polyvalent dysentery bacteriophage in a dry and stable form: I. Preliminary investigations and general procedures. J. Bacteriol. 46, 463-473.
121. Schade, A., and Caroline, L. (1944b). The preparation of polyvalent dysentery bacteriophage in a dry and stable form. II. Factors affecting the stabilization of dysentery bacteriophage during lyophilization. J. Bacteriol. 48, 179-190.
122. Schade, A., and Caroline, L. (1944c). The preparation of polyvalent dysentery bacteriophage in a dry and stable form. III. Stability of the dried bacteriophage towards heat, humidity, age and acidity. J. Bacteriol. 48, 243-251.
123. Schmerer, M., Molineux, I. J., and Bull, J. J. (2014). Synergy as a rationale for phage therapy using phage cocktails. PeerJ 2:e590. doi: 10.7717/peerj.590
124. Seed, K. D., Lazinski, D. W., Calderwood, S. B., and Camilli, A. (2013). A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature 494, 489-491. doi: 10.1038/nature11927
125. Shukla, K. S., Hirpurkar, S. D., Singh, S. K., and Rajoria, R. (2014). Isolation of phage from animal waste of different LSF and their utility in phage therapy. Int. J. Curr. Microbiol. Appl. Sci. 3, 205-210.
126. Skurnik, M., Pajunen, M., and Kiljunen, S. (2007). Biotechnological challenges of phage therapy. Biotechnol. Lett. 29, 995-1003. doi: 10.1007/s10529-007-9346-1
127. Skurnik, M., and Strauch, E. (2006). Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296, 5-14. doi: 10.1016/j.ijmm.2005.09.002
128. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
129. Synnott, A. J., Kuang, Y., Kurimoto, M., Yamamichi, K., Iwano, H., and Tanji, Y. (2009). Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities. Appl. Environ. Microbiol. 75, 4483-4490. doi: 10.1128/AEM.02641-08
130. Szczepankowska, A. (2012). Role of CRISPR/cas system in the development of bacteriophage resistance. Adv. Virus Res. 82, 289-338. doi: 10.1016/B978-0-12-394621-8.00011-X
131. Tanji, Y., Mizoguchi, K., Yoichi, M., Morita, M., Hori, K., and Unno, H. (2002). Fate of coliphage in a wastewater treatment process. J. Biosci. Bioeng. 94, 172-174. doi: 10.1016/S1389-1723(02)80139-6
132. Tovkach, F. I., Zhuminska, G. I., and Kushkina, A. I. (2012). Long-term preservation of unstable bacteriophages of enterobacteria. Mikrobiol. Z. 74, 60-66.
133. Ul Haq, I., Chaudhry, W. N., Andleeb, S., and Qadr, I. I (2011). Isolation and partial characterization of a virulent bacteriophage IHQ1 specific for Aeromonas punctata from stream water. Microb. Ecol. 63, 954-963. doi: 10.1007/s00248-011-9944-2
134. Vandenheuvel, D., Lavigne, R., and Brüssow, H. (2015). Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu. Rev. Virol. 2, 599-618. doi: 10.1146/annurev-virology-100114-054915
135. Vandersteegen, K., Kropinski, A. M., Nash, J. H., Noben, J. P., Hermans, K., and Lavigne, R. (2013). Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications. J. Virol. 87, 3237-3247. doi: 10.1128/JVI.02763-12
136. Verthé, K., Possemiers, S., Boon, N., Vaneechoutte, M., and Verstraete, W. (2004). Stability and activity of an Enterobacter aerogenes-specific bacteriophage under simulated gastro-intestinal conditions. Appl. Microbiol. Biotechnol. 65, 465-472. doi: 10.1007/s00253-004-1585-7
137. Vinodkumar Srinivasa, H., Basavarajappa, K. G., Geethalakshmi, S., and Bandekar, N. (2011). Isolation of bacteriophages to multi-drug resistant Enterococci obtained from diabetic foot: a novel antimicrobial agent waiting in the shelf? Indian J. Pathol. Microbiol. 54, 90-95. doi: 10.4103/0377-4929.77333
138. Wanninger, I., and Artz, C. (2009). A new solution for endotoxin removal in biomanufacturing processes. Bioprocess Int. 7:87.
139. Weber-Dabrowska, B., Mulczyk, M., and Górski, A. (2000a). Bacteriophage therapy of bacterial infections: an update of our Institute's experience. Arch. Immunol. Ther. Exp. (Warsz) 48, 547-551.
140. Weber-Dabrowska, B., Mulczyk, M., and Górski, A. (2001). Bacteriophage therapy for infections in cancer patients. Clin. Appl. Immunol. Rev. 1, 131-134. doi: 10.1016/S1529-1049(01)00015-0
141. Weber-Dabrowska, B., Mulczyk, M., and Górski, A. (2003). Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant Proc. 35, 1385-1386. doi: 10.1016/S0041-1345(03)00525-62014
142. Weber-Dabrowska, B., Zaczek, M., Dziedzic, B., Lusiak-Szelachowska, M., Kiejzik, M., Górski, A., et al. (2014). "Bacteriophages in green biotechnology-the utilization of drinking water, " in Industrial, Medical and Environmental Applications of Microorganisms: Current Status and Trends, ed. A. Méndez-Vilas (Wageningen: Wageningen Academic Publishers), 500-504.
143. Weber-Dabrowska, B., Zimecki, M., and Mulczyk, M. (2000b). Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp. 48, 31-37.
144. Weigle, J. J. (1953). Induction of mutations in a bacterial virus. Proc. Natl. Acad. Sci. U.S.A. 39, 628-636. doi: 10.1073/pnas.39.7.628
145. Weld, R. J., Butts, C., and Heinemann, J. A. (2004). Models of phage growth and their applicability to phage therapy. J. Theor. Biol. 227, 1-11. doi: 10.1016/S0022-5193(03)00262-5
146. WHO (2014). Antimicrobial Resistance: Global Report on Surveillance. World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf
147. Wittebole, X., De Roock, S., and Opal, S. M. (2014). A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5, 226-235. doi: 10.4161/viru.25991
148. Wommack, K. E., and Colwell, R. R. (2000). Virioplankton: viruses in aquatic ecosystems. Microbiol. Mol. Biol. Rev. 64, 69-114. doi: 10.1128/MMBR.64.1.69-114.2000
149. Yu, P., Mathieu, J., Li, M., Dai, Z., and Alvarez, P. J. (2015). Isolation of polyvalent bacteriophages by sequential multiple-host approaches. Appl. Environ. Microbiol. 20, 808-815. doi: 10.1128/AEM.02382-15
150. Zaczek, M., Weber-Dabrowska, B., Lusiak-Szelachowska, M., Kurzêpa, A., Skaradziñski, G., Dziedzic, B., et al. (2011). "Application of tetrazolium for qualitative and quantitative colorimetric testing of phage lysis, " in Proceedings of the First International Oxford Bacteriophage Conference and Exhibition (Oxford: St Hilda's College).
151. Zhan, A., Buchan, A., and Chen, F. (2015). Novel N4 bacteriophages prevail in the cold biosphere. Appl. Environ. Microbiol. 81, 5196-5202. doi: 10.1128/AEM.00832-15
152. Zheng, C., Wang, G., Liu, J., Song, C., Gao, H., and Liu, X. (2013). Characterization of the major capsid genes (g23) of T4-type bacteriophages in the wetlands of northeast China. Microb. Ecol. 65, 616-625. doi: 10.1007/s00248-012-0158
153. Zheng, Z., Bao, M., Wu, F., Chen, J., and Deng, X. (2016). Predominance of single prophage carryinga CRISPR/cas system in "Candidatus Liberibacter asiaticus" strains in Southern China. PLoS ONE 11:e0146422. doi: 10.1371/journal.pone.0146422